Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Stella

Home/COPD (Chronic Obstructive Pulmonary Disease)/

View on ClinicalTrials.gov

Recruiting

Back to COPD (Chronic Obstructive Pulmonary Disease) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Duke Asthma Allergy and Airway Center, Durham, North Carolina

Key details

Phase

Safety & dosing

Sponsor

Bastiaan Driehuys

Collaborators

United Therapeutics

Enrollment target

~10 participants

Started

September 2025

Primary completion

July 2027

Age range

40 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.